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Background:  Dabigatran  has  demonstrated  promising  results  for  the  prevention  of strokes  in patients  with
non-valvular  atrial  ﬁbrillation  (NVAF).  However,  there  have  been  episodes  of  major  bleeding,  especially
in  elderly  patients  or those  with renal  dysfunction.  The  purpose  of  this  study  was  to  retrospectively
examine  the  relationship  between  the bleeding  events  and  activated  partial  thromboplastin  time  (APTT)
values  under  dabigatran  usage  in  the  everyday  clinical  practice.  Moreover,  we  investigated  which  factors
would  contribute  to the  APTT  values.
Methods and  results:  A  total  of 139  NVAF  patients  (112  men,  65  ±  11  years)  were  included.  We evaluated
the  inﬂuence  of  the putative  etiological  variables  and  the  bleeding  score,  HAS-BLED  score,  on  APTT  values:
age  greater  than  70 years,  renal  function,  gender,  dose  of  dabigatran,  and  the  concomitant  prescription
of  a P-glycoprotein  inhibitor.  There  were  50 patients  with  an  age  of  ≥70 years  (36.0%).  A  P-glycoprotein
inhibitor  was  administered  in 18  patients.  During  the observation  period  (median  120  days)  there  was
1  episode  of asymptomatic  cerebral  infarction.  There  were  no intrinsic  major  bleeding  events,  however,
11  patients  had  minor  hemorrhagic  events.  The  results  of the  APTT  measurements  exhibited  a  variety  of
values  both  among  inter-  and  intra-individuals.  On  multivariable  analysis,  signiﬁcant  associations  were
found  between  the  following  risk factors  and  the APTT  values:  creatinine  clearance,  dose  of  dabigatran,
and  concomitant  use  of  a  P-glycoprotein  inhibitor.  The  minor  bleeding  events  did  not correlate  with  the
APTT  values,  nor  HAS-BLED  score.
Conclusions: The  APTT  values  became  prolonged  under  dabigatran  usage  and  exhibited  a  remarkable
diversity.  Although  major  bleeding  did  not  occur  unless  APTT  was  prolonged  excessively,  minor  bleeding
arose  irrespective  of  the APTT  values  even  within  the range  of  the  APTT  values  not  exceeding  80  s.
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ntroduction
Dabigatran etexilate, an oral direct thrombin inhibitor, has
ecently been used for the prevention of strokes and systemic
mboli in patients with non-valvular atrial ﬁbrillation (NVAF)
1,2]. It rapidly undergoes hydrolysis to its active form, dabi-
atran. Due to a ﬁxed dosing and predictable pharmacology,
outine laboratory coagulation monitoring under dabigatran is
eemed unnecessary. Commonly available global coagulation-time
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assessments may  assist in the clinical management by indicat-
ing severe accumulation of dabigatran. It has been reported that
activated partial thromboplastin time (APTT) may  be useful for a
qualitative assessment and is correlated with the plasma concen-
tration of dabigatran [3,4].
Anticoagulation  therapy for thromboprophylaxis has another
aspect of serious hemorrhage. As dabigatran has been used widely,
there have been episodes of major bleeding due to dabiga-
tran, including in some patients whose APTT values exhibited an
excessive prolongation (>80 s), which resulted in death due to
uncontrolled bleeding. Elderly patients with impaired renal func-
tion or low body weight tended to have severe bleeding due to the
prescription of dabigatran [5–8]. On the other hand, a wide distri-
bution of APTT values in Japanese NVAF patients under dabigatran
therapy was observed [9]. The bleeding risk estimation is important
vier Ltd. All rights reserved.
1  of Car
i
t
o
(
u
i
c
c
M
a
i
t
t
i
w
w
t
t
s
a
D
t
m
n
m
(
(
a
[
f
f
d
a
h
P
p
t
d
e
s
o
i
p
p
o
z
s
A
S
o
w
m
v
v
minor bleeding events in 10 patients (subcutaneous bleeding in
3, hemorrhage in the fundus of the eye, subconjunctival hemor-
rhage, and hemorrhoidal bleeding in 2 each, and hematuria, and
nasal bleeding in 1 each), dyspepsia in 14, liver dysfunction in 3,
Table 1
Baseline characteristics of our population.
Study population (n = 139)
Age (years) 65 ± 11
Male (%) 81
Type  of AF (%) (paroxysmal/persistent) 51/49
Daily  dose of dabigatran
300  mg/220 mg/150 mg,  110 mg (%)
3/52/4/1
CHA2DS2-VASc score, ≥2 points (%) 1.8 ± 1.3, 54
Hemoglobin (mg/dl) 14  ± 2
eGFR (ml/min/1.73 m2) 68 ± 15
Ccr (Cockcroft-Gault) (ml/min) 96 ± 41
Body weight (kg) 68 ± 14
Antiplatelet drugs (%) 1222 M. Kawabata et al. / Journal
n clinical management. Among some bleeding scores, Hyper-
ension, Abnormal renal/liver function, Stroke, Bleeding history
r predisposition, Labile international normalized ratio, Elderly
>65 years), Drugs/alcohol concomitantly (HAS-BLED) score was
sed in the guidelines [10,11].
In this study we examined the relationship between the bleed-
ng events and APTT values under dabigatran usage in everyday
linical practice. Moreover, we investigated which factors would
ontribute to the APTT values.
ethods
NVAF patients treated with dabigatran between April 2011
nd July 2012, and who were followed until October 2012 were
ncluded. The follow-up was ceased when dabigatran was  discon-
inued or the patient transferred to another hospital. We  checked
he clinical and demographic data, including the other medications,
ncidence of side effects, and APTT values (normal range, 25–27 s),
hich were obtained from the medical records. Major bleeding
as deﬁned as intrinsic bleeding associated with a reduction in
he hemoglobin level of ≥2.0 g/dl, or which required hospitaliza-
ion. Other bleeding was deﬁned as minor bleeding. CHA2DS2-VASc
core was evaluated for risk stratiﬁcation of thromboembolism in
ll subjects [12,13]. The Ethical Committee at Tokyo Medical and
ental University granted permission for this study.
Since the effect of dabigatran on the APTT values might be
hought to indicate large differences among individuals [9], the
ean APTT-value in each patient was used for the analysis, so as
ot to be affected by speciﬁc subjects whose APTT values had been
easured much more frequently than others.
The renal function was evaluated using creatinine clearance
Ccr) (ml/min) [calculated by (140 − age [years]) × body weight
kg)/72/serum creatinine (Scr) (mg/dl), and ×0.85 if female] [14]
nd estimated glomerular ﬁltration rate (eGFR) (ml/min/1.73 m2)
calculated by 194 × Scr−1.094 × age (years)−0.287, and ×0.739 if
emale] [15], and those mean values in each patient were also used
or the analysis like the APTT values.
In Japan, the recommended dose of dabigatran is 150 mg  twice
aily, and 110 mg  twice daily can be considered in patients with
n age ≥70 years, moderate renal impairment (Ccr 30–50 ml/min),
istory of gastrointestinal bleeding, or those taking a concomitant
-glycoprotein inhibitor. The drug should be contraindicated in
atients with severe renal impairment (Ccr < 30 ml/min).
In  this study, the dose of dabigatran and the sampling time of
he APTT values were determined by each of the physicians in their
aily clinical practice. We  evaluated the inﬂuence of the putative
tiological variables and HAS-BLED score on the APTT values retro-
pectively: age greater than 70 years, renal function, gender, dose
f dabigatran, and the concomitant prescription of a P-glycoprotein
nhibitor. If there was a change in the dose of dabigatran or the
rescription of a P-glycoprotein inhibitor during the observation
eriod, the APTT value data in those patients were obtained for each
f those situations. Among the P-glycoprotein inhibitors, ketocona-
ole, amiodarone, verapamil, and quinidine were included in this
tudy [16–20]. The relationship between the bleeding events and
PTT values under dabigatran was also examined.
tatistical methods
All  data are expressed as the mean ± standard deviation (SD)
r numbers and percentages of patients. A multivariate analysis
as performed using multiple linear regression analyses to deter-
ine the presence of an association between the APTT values and
ariables tested, using the previously mentioned covariables. A uni-
ariate analysis of the factors associated with bleeding events wasdiology 62 (2013) 121–126
performed  with the t-test for continuous variables and the Chi2
test for nominal variables. Then a logistic regression analysis was
performed to determine the independent predictors of bleeding
events. p-Values of <0.05 were considered statistically signiﬁcant.
SPSS version 11.0.1 software (SAS Institute, Cary, NC, USA) was used
for all statistical analyses.
Results
A  total of 139 NVAF patients (112 men  and 27 women, mean age
65 ± 11 years) were included in this study. There were 50 patients
with an age of ≥70 years (36.0%). The CHA2DS2-VASc score ranged
from 0 to 6, and 75 patients (54.0%) had a score of ≥2. The pre-
scribed dose of dabigatran was  300 mg/day in 60, 220 mg/day in 72,
150 mg/day in 5, and 110 mg/day in 2. A reduced dose was applied
because of a high age, renal impairment, or concomitant use of a P-
glycoprotein inhibitor. The mean eGFR was  68 ± 15 ml/min/1.73 m2
and the mean Ccr was 96 ± 41 ml/min. The median follow-up dura-
tion was  120 days (range 1–546, average 149 days). Among the
aforesaid P-glycoprotein inhibitors only verapamil was given in 18
(12.9%). The baseline characteristics of the patients are shown in
Table 1.
Over  the course of the follow-up period, an 86-year-old male
taking clarithromycin, a P-glycoprotein inhibitor, had asymp-
tomatic cerebral infarction. His CHA2DS2-VASc score was  2 and
HAS-BLED score 1. Although he received 75 mg  dabigatran twice
daily, he decreased it to 75 mg  once daily due to subcutaneous
bleeding and nasal bleeding by his own decision. As the onset
of cerebral infarction was  unknown, the exact dose of dabiga-
tran related to this event was unclear. The APTT was 35–40 s
with 75 mg  dabigatran twice daily before the cerebral infarc-
tion, however, it prolonged to 60.7 s after the event with the
same dose of dabigatran. As a result, dabigatran was switched to
warfarin.
Adverse effects occurred in 32 (23%) patients including
15 patients who  discontinued dabigatran because of side effects.
There were no major bleeding events. Only one patient had an
intracranial bleeding event, however, it was  traumatic subarach-
noid hemorrhage (SAH). He was  a 50-year-old man and took his
ﬁrst dabigatran dose of 150 mg  and had some alcohol. He then fell
down, and had a transient loss of consciousness. He was  diagnosed
with brain contusion and SAH. At that time his APTT value was
40.4 s. No increase in the intracranial bleeding occurred after that
and no symptoms remained. Other recorded adverse effects wereP-glycoprotein inhibitor (%) 13
Follow-up duration (days) 149 ± 125
The values are the mean ± SD or %. AF, atrial ﬁbrillation; Ccr, creatinine clearance;
eGFR,  estimated glomerular ﬁltration rate.
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Table  2
Patients with minor bleeding events.
Patient
(years/gender)
Type of bleeding Dose of dabigatran
(mg/day)
Ccr
(ml/min)
eGFR
(ml/min/1.73 m2)
HAS-BLED
score
APTT (s) P-glycoprotein
inhibitor
Body
weight (kg)
66, male Hemorrhoidal 220 79.6 68.8 1 33.7 No 67
86,  male Nasal,
subcutaneous
150  45 69 1 39.7 Yes
(clarithromycin)
48
64,  male Hemorrhoidal 220 88.7 84.2 1 34 No 61
78,  female Subcutaneous 300 54.1 61.6 1 No No 51
50,  male Traumatic SAH 300 103.4 79.5 0 40.4 No 67
65,  male In the fundus of
the  eye
300 62.3 51.7 1 48.6 No 67
75,  male Subconjunctival 220 62.4 58.1 1 54.6 No 67
69,  male In the fundus of
the  eye
220 63.2 65.4 2 54.3 No 57
68,  male Hematruia 220 59.2 53.7 1 No No 63
69,  female Subcutaneous 220 58.5 57.4 1 59 Yes (verapamil) 53
68,  male Subconjunctival 300 62.2 64.9 1 74.3 Yes (verapamil) 56
APTT, activated partial thromboplastin time; Ccr, creatinine clearance; eGFR, estimated glomerular ﬁltration rate; SAH, subarachnoid hemorrhage.
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rnd skin rash, pancytopenia, cough, and diarrhea in 1 each. Table 2
hows the patients who  had minor bleeding events. The APTT val-
es which were obtained just before or after the minor bleeding
vents are described.
PTT  values
A  total of 401 APTT values were obtained in 123 patients (1–16
ata values per patient). The dose of dabigatran was  changed in
4 and the concomitant use of verapamil was altered in 6 patients,
o 2 different mean APTT values were obtained from 20 patients.
t last 143 mean APTT values were analyzed in this study. Fig. 1
hows the scatter plots of the APTT values and age (at doses of
00 mg/day (a) and 220 mg/day (b), respectively), which exhibit a
ide range of values. There were 17 patients who had their APTT
easured more than 5 times around similar sampling time with
he same dose of dabigatran. Their standard deviation ranged from
.8 to 11.2 s.
ig. 1. Distribution of activated partial thromboplastin time (APTT) values in rela-
ion to the patients’ age (a) at a dabigatran dose of 300 mg/day and (b) 220 mg/day,
espectively.  The APTT-values exhibited a wide range of values.At a dose of 300 mg/day, the mean APTT values that were
derived numbered 48 (average 41.0 s) in the morning and 26 in the
afternoon (average 42.6 s), while at a dose of 220 mg/day, 46 data
values were obtained in the morning (average 42.4 s) and 35 in
the afternoon (average 46.1 s) (Fig. 2). There were 22 patients who
had their APTT values examined both in the morning and in the
afternoon. The APTT values were more prolonged in the morning
in some patients, however, in others they were more prolonged in
the afternoon (Fig. 3).
Inﬂuential  factors of the APTT values
A multivariable analysis showed that Ccr, dose of dabigatran,
and concomitant use of a P-glycoprotein inhibitor were indepen-
dent factors related to the APTT values (Table 3). By a univariate
analysis, only Ccr and body weight signiﬁcantly correlated with the
minor bleeding events (Table 4). The APTT values were not associ-
ated with the minor bleeding events. These same variables were
then entered into a multivariable model to evaluate the presence
of an association with the minor bleeding events, however, this
Fig. 2. The activated partial thromboplastin time (APTT) values in the morning and
afternoon at a dabigatran dose of 300 mg/day and 220 mg/day, respectively. At a dose
of 300 mg/day, the mean APTT value was 41.0 ± 8.6 s in the morning and 42.6 ± 10.6 s
in the afternoon, while at a dose of 220 mg/day, it was 42.4 ± 10.7 s in the morning
and  46.1 ± 10.4 s in the afternoon.
124 M. Kawabata et al. / Journal of Car
Fig. 3. The comparison of the activated partial thromboplastin time (APTT) values
in the morning and in the afternoon in 22 patients.
Table 3
Multivariate analysis of the correlates of the activated partial thromboplastin time-
values.
p value
Age greater than 70 years 0.856
Creatinine clearance (Cockcroft-Gault) 0.001
Estimated glomerular ﬁltration rate 0.947
Gender 0.876
Dose of dabigatran 0.024
Concomitant P-glycoprotein inhibitor <0.0001
HAS-BLED score 0.203
Table 4
Univariate predictive factors of minor bleeding events in the overall population.
Bleeding group
(n  = 11)
No  bleeding
group (n = 128)
p  value
Age (years) 69 ± 9 65 ± 11 0.11
Male (%) 82 80 0.91
Daily dose of
dabigatran (mg)
243 ± 50 252 ± 51 0.1
APTT (s) 41.4 ± 13.3 42.0 ± 10.2 0.27
eGFR
(ml/min/1.73 m2)
64.9 ± 10.1 66.6 ± 15.8 0.22
Ccr
(Cockcroft-Gault)
(ml/min)
67.1  ± 16.8 83.0 ± 33.8 0.001
Body weight (kg) 59.7 ± 7.1 67.6 ± 14.4 0.003
HAS-BLED score 1.0 ± 0.4 0.7 ± 0.7 0.21
P-glycoprotein
inhibitor (%)
27 12 0.14
Data are expressed as the mean values ± SD, or number (%). APTT, activated par-
tial thromboplastin time; Ccr, creatinine clearance; eGFR, estimated glomerular
ﬁltration  rate.diology 62 (2013) 121–126
association did not reach statistical signiﬁcance (p = 0.19 for Ccr and
p = 0.57 for body weight).
Discussion
This study was an assessment of the bleeding events and the
APTT values with dabigatran among NVAF patients in clinical
practice. The APTT values were prolonged under dabigatran usage
and exhibited a variety of values. On multivariable analysis, signiﬁ-
cant associations were found between the following risk factors and
the APTT values: creatinine clearance, dose of dabigatran, and con-
comitant use of a P-glycoprotein inhibitor. In this study there were
no patients with an excessive APTT prolongation, nor any intrin-
sic major bleeding events. The minor hemorrhagic events did not
correlate with the APTT values.
Dabigatran, with its convenient oral administration, may
improve the adherence and quality of life in patients, which could
result in a reduction in the rate of strokes in NVAF patients [1,2].
It is expected that dabigatran will likely extend its administra-
tion in elderly patients. However, major bleeding events have been
reported in this frail elderly population [5–8]. Dabigatran is elim-
inated predominantly (85%) by the kidneys, and renal functional
impairment is likely to cause drug overexposure due to prolonged
excretion rates and accumulation of the drug [21]. At the same time,
there is an inverse relationship between the renal function and age
[14]. An impaired renal function, often in the presence of a nor-
mal serum creatinine level, is common yet frequently overlooked
among elderly patients. A low body weight also further exagger-
ates the magnitude of the under ascertainment of an impaired renal
function [22]. Therefore, the risk of major overdosage of dabigatran
in this population is much increased causing severe bleeding. In this
study Ccr which includes the body weight in its formula, but not
eGFR which does not contain the body weight in the equation, was
revealed as an independent factor which affected the APTT values.
We highlighted that not only the renal function but also the body
weight is an important key point in the prescription of dabigatran
in the elderly population. In this study the correlation between the
APTT values and the patient’s age was not obvious. One  of the rea-
sons might be that the dose of dabigatran was  determined due to
patient’s age, so there was  an artiﬁcial bias.
Since dabigatran etexilate is a substrate of P-glycoprotein [16], it
has few drug interactions except for that involving P-glycoprotein
agents. Inhibitors of P-glycoprotein such as ketoconazole, amio-
darone, verapamil, and quinidine may  increase the peak plasma
concentrations of dabigatran [17,18], while atorvastatin, also a
P-glycoprotein inhibitor, results in no signiﬁcant change in the
pharmacokinetic parameters of dabigatran [19]. For that reason
we included only ketoconazole, amiodarone, verapamil, and quini-
dine as concomitant P-glycoprotein inhibitors, and among them
just verapamil was given in this study. The presence of verapamil
was an independent factor which inﬂuenced the APTT-values. NVAF
patients who  have an indication for dabigatran might also need
rate control for AF, and from this point of view verapamil might
frequently be given together. We  should pay thorough attention in
such cases.
The  only patient who  had asymptomatic cerebral infarc-
tion during the observation period received clarithromycin, a
P-glycoprotein inhibitor. He also had two minor bleeding events.
The APTT values in this patient were unsteady and ﬁnally dabiga-
tran was  switched to warfarin. The co-administration of dabigatran
with clarithromycin might result in a possibility of increasing the
plasma concentration of dabigatran, which is not so striking com-
pared to other P-glycoprotein inhibitors such as verapamil [20]. The
use of dabigatran together with clarithromycin might have made it
difﬁcult to have controlled the coagulation state in this patient.
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In previous reports the effects on APTT by dabigatran were con-
entration dependent, indicating that APTT prolonged more at a
eak concentration than at a trough concentration [4]. It is specu-
ated that APTT is altered according to the sampling time in clinical
ractice. However, there was little difference in the APTT-values
btained at the peak and trough levels or in the morning and
fternoon at the outpatient clinic in a previous report [9]. In our
opulation there were some patients who revealed longer APTT
alues in the afternoon than in the morning and others showed
he opposite. Moreover, dabigatran demonstrated variable effects
n the APTT values even within individuals, thus this considerable
ntraindividual variability might exceed the reported differences
etween the peak and trough APTT values. Further, dabigatran
eaches a peak plasma concentration in 1.5–3 h [4,23], however, it
as been shown to be delayed to closer to 6 h following hip arthro-
lasty with a slower rate and extent of absorption [24]. Therefore,
e considered that the APTT value at any time was well worth eval-
ating in clinical practice and did not take the sampling time into
ccount. As dabigatran’s mean absolute bioavailability remains at
nly 6.5% [16,25], such a large difference in its coagulation effect
ight be observed.
Although the APTT results demonstrated a wide range of values
s in previous reports [3,4,9,16], there were no patients with an
xcessive APTT prolongation or any intrinsic major bleeding in this
tudy. On the other hand, the APTT-results had no relationship to
he minor hemorrhagic events, nor HAS-BLED score as in a previous
eport [26]. The HAS-BLED score is a practical bleeding risk score
n AF patients [10,11]. Another novel bleeding risk score is needed
or AF patients taking dabigatran or other novel oral anticoagulant
rugs in the future. Concomitant P-glycoprotein inhibitors should
e included in such a score.
imitations
First, we did not assay the plasma concentration of dabiga-
ran. Second, our results were obtained retrospectively from an
nselected and limited population with a small number and short
bservation period from a single center. Patients with a high risk
or a thromboembolism (high CHA2DS2-VASc score) or severe renal
ysfunction were not sufﬁciently evaluated. There were a few cases
aking dabigatran with doses that were not recommended. The pre-
cription of dabigatran was based not on any medical evidence but
nly each physician’s decision. Therefore, the results should not
e directly extrapolated to all populations. The evaluation of more
atients with a longer observation time is needed in the future.
hird, this study essentially depended on the patients’ compliance.
inally, the thrombin clotting time and ecarin clotting time are the
ost sensitive clotting assays for the detection of dabigatran in
he blood [4]. However, they are not routinely available in clinical
ractice, while APTT can be assessed easily and might be a practical
ool to take care of real-world AF patients.
linical implications
The  APTT value would not be prolonged excessively as long as
he instructions for the prescription of dabigatran are followed, and
ajor bleeding would not occur within such APTT values. In the
etermination of the dose of dabigatran, creatinine clearance or
oncomitant use of a P-glycoprotein inhibitor should particularly
e assessed.onclusions
The APTT values prolonged under dabigatran usage and exhib-
ted a remarkable diversity. Although major bleeding did not occur
[
[diology 62 (2013) 121–126 125
unless the APTT value was  excessively prolonged, minor bleeding
arose irrespective of the APTT values even within the range of APTT
values not exceeding 80 s.
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